National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

This is VAERS ID 858738

History of Changes from the VAERS Wayback Machine

First Appeared on 6/13/2020

VAERS ID: 858738
VAERS Form:2
Vaccin­ation / Manu­facturer Lot / Dose Site / Route

Administered by: Other      Purchased by: ??
Symptoms: Death, Meningitis pneumococcal, Pyrexia

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died:0000-00-00
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days:     Extended hospital stay? No
Previous Vaccinations:
Other Medications: Bexsero
Current Illness:
Preexisting Conditions:
Diagnostic Lab Data:

Write-up: Pneumococcal meningitis; Fever; Death; This case was reported by a physician via sales rep and described the occurrence of unknown cause of death in a 6-month-old female patient who received Men B NVS (Bexsero) for prophylaxis. Concomitant products included Men B NVS (Bexsero). On 20th December 2019, the patient received the 2nd dose of Bexsero. In December 2019, less than a week after receiving Bexsero and an unknown time after receiving Bexsero, the patient experienced pneumococcal meningitis (serious criteria hospitalization and GSK medically significant) and fever (serious criteria hospitalization). On 24th December 2019, the patient experienced unknown cause of death (serious criteria death, hospitalization and GSK medically significant). On an unknown date, the outcome of the unknown cause of death was fatal and the outcome of the pneumococcal meningitis and fever were unknown. It was unknown if the reporter considered the unknown cause of death, pneumococcal meningitis and fever to be related to Bexsero. Additional deatils were provided as follows: The age at vaccination was not reported. The patient received 1st dose of Bexsero 2 months before 2nd dose. Four days after vaccination with 2nd dose of Bexseo, the patient had death. After vaccination. patient experienced fever and hospitalised and documented with pneumococcal meningitis. The reporter stated that, It was unknown whether or not the pneumococcal meningitis was the reason for the death. The reporter stated that the final report on the death was under process and should be issued in 2 weeks now on. The physician did not agree to follow with safety as the final medical document was not prepared yet. It was expected to be available in two weeks on and then the physician may reconsider her decision for a follow up with safety Glaxosmithkline. The reporter did not consent to follow up.

New Search

Link To This Search Result:

Copyright © 2020 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166